CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.34B
This Quarter Return
+1.24%
1 Year Return
+85.27%
3 Year Return
+2,244.39%
5 Year Return
+2,846.94%
10 Year Return
+51,155.97%
AUM
$2.46B
AUM Growth
+$2.46B
(-4%)
Cap. Flow
+$92.2M
Cap. Flow
% of AUM
3.75%
Top 10 Holdings %
Top 10 Hldgs %
47.28%
Holding
111
New
8
Increased
8
Reduced
35
Closed
20
Top Buys
| 1 |
Erasca
ERAS
|
$217M |
| 2 |
Immuneering
IMRX
|
$58.5M |
| 3 |
Tango Therapeutics
TNGX
|
$38.8M |
| 4 |
Cytokinetics
CYTK
|
$35.7M |
| 5 |
Tyra Biosciences
TYRA
|
$18.2M |
Top Sells
| 1 |
Atea Pharmaceuticals
AVIR
|
$52M |
| 2 |
Astria Therapeutics
ATXS
|
$26.5M |
| 3 |
Twist Bioscience
TWST
|
$24.7M |
| 4 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$22M |
| 5 |
908 Devices
MASS
|
$21.1M |
Sector Composition
| 1 | Healthcare | 99.61% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Erasca
ERAS
$445M
| $217M | 8.81% | +10,505,550 | New | +$217M |
|
|
TPTX
2
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $189M | 7.67% | 2,842,297 -194,745 | -6% | -$12.9M |
|
|
3
Atea Pharmaceuticals
AVIR
$267M
| $173M | 7.02% | 4,928,756 -1,482,599 | -23% | -$52M |
|
|
FMTX
4
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $109M | 4.45% | 4,720,495 -1,094 | -0% | -$25.4K |
|
5
Revolution Medicines
RVMD
$7.1B
| $86.5M | 3.52% | 3,144,700 -193,466 | -6% | -$5.32M |
|
6
Olema Pharmaceuticals
OLMA
$375M
| $84.7M | 3.44% | 3,073,485 | – | – |
|
7
BridgeBio Pharma
BBIO
$9.89B
| $82.9M | 3.37% | 1,768,909 -112,071 | -6% | -$5.25M |
|
8
Design Therapeutics
DSGN
$315M
| $78.8M | 3.2% | 5,364,850 -50,000 | -0.9% | -$735K |
|
9
ALX Oncology
ALXO
$62.7M
| $74.8M | 3.04% | 1,012,079 +122,625 | +14% | +$9.06M |
|
10
Monte Rosa Therapeutics
GLUE
$296M
| $68M | 2.76% | 3,102,199 -91,774 | -3% | -$2.01M |
|
|
11
Immuneering
IMRX
$245M
| $58.5M | 2.38% | +2,252,626 | New | +$58.5M |
|
12
Edgewise Therapeutics
EWTX
$1.51B
| $56M | 2.27% | 3,370,914 +230,000 | +7% | +$3.82M |
|
13
BioAtla
BCAB
$26.7M
| $53.5M | 2.17% | 1,815,546 -136,172 | -7% | -$4.01M |
|
14
Avidity Biosciences
RNA
$5.99B
| $53.3M | 2.16% | 2,162,115 -66,552 | -3% | -$1.64M |
|
|
15
Tango Therapeutics
TNGX
$747M
| $48.8M | 1.98% | 3,899,185 +3,099,185 | +387% | +$38.8M |
|
|
RXDX
16
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $43.8M | 1.78% | 1,848,024 | – | – |
|
|
JBIO
17
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $42M | 1.71% | 2,030,691 | – | – |
|
18
Biomea Fusion
BMEA
$116M
| $38M | 1.54% | 3,170,872 | – | – |
|
|
19
Cytokinetics
CYTK
$4.23B
| $35.7M | 1.45% | +1,000,000 | New | +$35.7M |
|
|
RAIN
20
DELISTED
Rain Oncology Inc. Common Stock
RAIN
| $34.8M | 1.41% | 2,326,660 -300,000 | -11% | -$4.49M |
|
|
AMAM
21
DELISTED
Ambrx Biopharma, Inc. Common Stock
AMAM
| $33.1M | 1.34% | 2,486,386 | – | – |
|
|
VERV
22
DELISTED
Verve Therapeutics
VERV
| $32.7M | 1.33% | 709,224 | – | – |
|
23
Stoke Therapeutics
STOK
$1.08B
| $32.5M | 1.32% | 1,278,276 | – | – |
|
24
Tarsus Pharmaceuticals
TARS
$2.47B
| $31.1M | 1.27% | 1,444,831 -69,438 | -5% | -$1.5M |
|
25
Apellis Pharmaceuticals
APLS
$3.48B
| $30.5M | 1.24% | 925,000 +75,000 | +9% | +$2.47M |
|